Where are we on the path to eliminate hepatitis C virus ?
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Change in Summary PRO<br />
Score From BL <strong>to</strong> EOT<br />
(scale: 0-100)*<br />
Pt-Reported Outcomes Improve With DAA<br />
Therapy<br />
• End-of-treatment changes from baseline in summary pt-reported outcomes<br />
am<strong>on</strong>g 818 pts treated with SOF/VEL or SOF + RBV in ASTRAL-2 (GT2) and<br />
ASTRAL-3 (GT3)<br />
10<br />
8<br />
6<br />
4<br />
2<br />
0<br />
-2<br />
-4<br />
-6<br />
-8<br />
P = .16<br />
SF-36:<br />
Physical<br />
Comp<strong>on</strong>ent<br />
Summary<br />
SOF + RBV<br />
P = .0001<br />
SF-36:<br />
Mental<br />
Comp<strong>on</strong>ent<br />
Summary<br />
SOF/VEL<br />
P = .0001 P = .0009<br />
FACIT-F:<br />
Fatigue<br />
FACIT-F:<br />
Total<br />
P = .0012<br />
CLDQ-<br />
HCV:<br />
Total<br />
P = .0024<br />
WPAI:SHP:<br />
Work<br />
Productivity<br />
P = .0002<br />
WPAI:SHP:<br />
Activity<br />
*Changes of > 2 points represent significant difference from BL within treatment group (P < .05).<br />
Younossi ZM, et al. Clin Infect Dis. 2016;63:1042-1048.<br />
18
Change language